Vepdegestrant

OncoPharm by OncoPharmPod

May 7, 202600:11:35Science & Medicine

The latest FDA drug approval is vepdegestrant, a heterobifunctional protein degrader, for ESR1 mutated breast cancer. We discuss what that actually means and some possible implications for clinical practice. Check out th...

Related Episodes

Continue listening to more episodes from OncoPharm.

Lirafugratinib + LITESPARK011

Oct 1, 2026 - 00:15:34

This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA ap...

PI3K Pathway Hyperglycemia

Sep 24, 2026 - 00:10:07

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia....

Neutropenic Diets & Lung Cancer Updates

Sep 17, 2026 - 00:14:18

This week's podcast discusses a recent meta-analysis on the benefit of a "neutropenic diet" in patients o...

How to Read a Press Release and Drug Shortage Help

Sep 10, 2026 - 00:14:49

Press Releases are an increasingly common method to learn about new/upcoming data. What can clinicians le...

Paradigm and Daraxonrasib in NSCLC

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Daraxonrasib, Zanidatamab, and CNS Lymphoma Updates

Aug 27, 2026 - 00:20:26

This week's pod has everything: 1. DDI information and dosing for daraxonrasib, now FDA approved and comm...

Iberdomide

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...

Kidney Cancer in a Nutshell

Aug 13, 2026 - 00:16:12

Overview of renal cell carcinoma Learning Oncology Companion: